159 related articles for article (PubMed ID: 1802533)
1. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis.
Ashtekar DR; Costa-Periera R; Shrinivasan T; Iyyer R; Vishvanathan N; Rittel W
Diagn Microbiol Infect Dis; 1991; 14(6):465-71. PubMed ID: 1802533
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.
Ashtekar DR; Costa-Perira R; Nagrajan K; Vishvanathan N; Bhatt AD; Rittel W
Antimicrob Agents Chemother; 1993 Feb; 37(2):183-6. PubMed ID: 8452346
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
Molina-Torres CA; Ocampo-Candiani J; Rendón A; Pucci MJ; Vera-Cabrera L
Antimicrob Agents Chemother; 2010 May; 54(5):2188-90. PubMed ID: 20231398
[TBL] [Abstract][Full Text] [Related]
4. In vitro bactericidal activity of oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex.
Rao M; Sood R; Malhotra S; Fatma T; Upadhyay DJ; Rattan A
J Chemother; 2006 Apr; 18(2):144-50. PubMed ID: 16736882
[TBL] [Abstract][Full Text] [Related]
5. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T
J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635
[TBL] [Abstract][Full Text] [Related]
6. Two groups of Mycobacterium avium complex strains determined according to the susceptibility to rifampicin and ansamycin.
Tsukamura M
Microbiol Immunol; 1987; 31(7):615-23. PubMed ID: 3125413
[TBL] [Abstract][Full Text] [Related]
7. New antimycobacterial 2,3-dihydro-1-alkylindole-2-thiones.
Waisser K; Heinisch L; Slosárek M; Janota J
Folia Microbiol (Praha); 2006; 51(1):25-6. PubMed ID: 16821707
[TBL] [Abstract][Full Text] [Related]
8. [Antimycobacterial activities of a new quinolone, sparfloxacin].
Tomioka H; Sato K; Saito H
Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089
[TBL] [Abstract][Full Text] [Related]
9. Antituberculosis agents. VI. Activity of a new ciprofloxacin derivative against Mycobacterium avium and some drug-resistant strains of Mycobacterium tuberculosis.
Foroumadi A; Soltani F; Moshafi MH
Boll Chim Farm; 2002; 141(5):394-6. PubMed ID: 12481384
[TBL] [Abstract][Full Text] [Related]
10. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
[TBL] [Abstract][Full Text] [Related]
11. Antituberculosis agents. IX. In vitro antimycobacterial activity of N-(2-phenyl-2-oxoethyl) and N-[2-(4-fluorophenyl)-2-oxoethyl]ciprofloxacin derivatives against some drug-resistant strains of Mycobacterium tuberculosis and Mycobacterium avium isolates.
Foroumadi A; Soltani F
Boll Chim Farm; 2003; 142(6):248-50. PubMed ID: 14606264
[TBL] [Abstract][Full Text] [Related]
12. New antimycobacterial S-alkylisothiosemicarbazones.
Waisser K; Heinisch L; Slosárek M; Janota J
Folia Microbiol (Praha); 2005; 50(6):479-81. PubMed ID: 16681143
[TBL] [Abstract][Full Text] [Related]
13. Use of the BACTEC system for drug susceptibility testing of Mycobacterium tuberculosis, M. kansasii, and M. avium complex.
Steadham JE; Stall SK; Simmank JL
Diagn Microbiol Infect Dis; 1985 Jan; 3(1):33-40. PubMed ID: 3917885
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Efficacy of Novel Oxazolidinone Analogues against Nontuberculous Mycobacteria In Vitro.
Zhao W; Jiang Y; Bao P; Li Y; Tang L; Zhou Y; Zhao Y
Jpn J Infect Dis; 2015; 68(6):520-2. PubMed ID: 25971324
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.
Sasaki H; Haraguchi Y; Itotani M; Kuroda H; Hashizume H; Tomishige T; Kawasaki M; Matsumoto M; Komatsu M; Tsubouchi H
J Med Chem; 2006 Dec; 49(26):7854-60. PubMed ID: 17181168
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
Dickinson JM; Mitchison DA
Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime.
Abate G; Hoffner SE
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):119-22. PubMed ID: 9294701
[TBL] [Abstract][Full Text] [Related]
18. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
Cynamon MH; Klemens SP; Sharpe CA; Chase S
Antimicrob Agents Chemother; 1999 May; 43(5):1189-91. PubMed ID: 10223934
[TBL] [Abstract][Full Text] [Related]
19. Activity of ciprofloxacin against Mycobacteria in vitro: comparison of BACTEC and macrobroth dilution methods.
Trimble KA; Clark RB; Sanders WE; Frankel JW; Cacciatore R; Valdez H
J Antimicrob Chemother; 1987 May; 19(5):617-22. PubMed ID: 3112096
[TBL] [Abstract][Full Text] [Related]
20. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria.
Banks J; Jenkins PA
Thorax; 1987 Nov; 42(11):838-42. PubMed ID: 3424264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
